MENU
+Compare
QNCX
Stock ticker: NASDAQ
AS OF
Jun 26, 04:59 PM (EDT)
Price
$1.52
Change
-$0.08 (-5.00%)
Capitalization
83.43M

QNCX Quince Therapeutics Forecast, Technical & Fundamental Analysis

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases... Show more

Industry: #Biotechnology
QNCX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for QNCX with price predictions
Jun 25, 2025

Momentum Indicator for QNCX turns positive, indicating new upward trend

QNCX saw its Momentum Indicator move above the 0 level on May 28, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for QNCX just turned positive on May 20, 2025. Looking at past instances where QNCX's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

QNCX moved above its 50-day moving average on June 05, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for QNCX crossed bullishly above the 50-day moving average on June 09, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where QNCX advanced for three days, in of 229 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 140 cases where QNCX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QNCX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

QNCX broke above its upper Bollinger Band on June 25, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. QNCX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.490) is normal, around the industry mean (16.539). P/E Ratio (0.000) is within average values for comparable stocks, (59.016). QNCX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.300). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (255.605).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QNCX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
QNCX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

QNCX is expected to report earnings to fall 33.09% to -22 cents per share on August 12

Quince Therapeutics QNCX Stock Earnings Reports
Q2'25
Est.
$-0.23
Q1'25
Missed
by $0.15
Q4'24
Missed
by $0.10
Q3'24
Missed
by $0.03
Q1'23
Missed
by $0.03
The last earnings report on May 13 showed earnings per share of -34 cents, missing the estimate of -18 cents. With 158.46K shares outstanding, the current market capitalization sits at 83.43M.
A.I. Advisor
published General Information

General Information

a developer of novel disease-modifying therapeutic for alzheimer's and other degenerative diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
611 Gateway Boulevard
Phone
+1 415 910-5717
Employees
32
Web
https://www.quincetx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BABB0.840.01
+0.61%
BAB, Inc.
GPHOF0.53N/A
+0.02%
Graphite One Inc.
WLMIY22.45-0.16
-0.73%
Wilmar International, Ltd.
IFNNY40.79-0.74
-1.78%
Infineon Technologies AG
WHGLY18.87-0.42
-2.18%
WH Group Ltd.

QNCX and Stocks

Correlation & Price change

A.I.dvisor tells us that QNCX and CCCC have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that QNCX and CCCC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QNCX
1D Price
Change %
QNCX100%
+10.34%
CCCC - QNCX
33%
Poorly correlated
-1.28%
MNPR - QNCX
32%
Poorly correlated
-4.14%
ADCT - QNCX
31%
Poorly correlated
-3.16%
CLNN - QNCX
29%
Poorly correlated
-0.49%
KOD - QNCX
28%
Poorly correlated
+2.22%
More